CUE Stock — Cue Biopharma Inc.: Cash, EV, Pipeline

Share price

$37.05

Market cap

$269.1M

Cash

$17.4M

Enterprise value

$251.7M

Balance sheet

Cash	$17.4M
Debt	$0.0M
Net cash	$17.4M
Enterprise value	$251.7M
Basic shares	7.3M shares
Fully diluted shares	17.6M shares
Fully diluted market cap	$651.3M
Cash per share	$2.39

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading CUE daily closes…

Loading price history…

Pipeline assets

CUE-221

Phase 2 · Active Modality: antibody (anti-IgE, dual-mechanism)

Aliases Ascendant-221

Target IgE

Partnerships Ascendant/UBI: License Agreement (Apr 30, 2026) — exclusive, sublicensable rights outside the Ascendant Territory; royalty payments on first commercial sale; top-up obligation on clinical milestones. Clinical trials being conducted by UBI/Ascendant in China

Indications

Allergic diseases (Phase 2)

Status note Lead asset; novel anti-IgE antibody with dual-mechanism in Phase 2 development for allergic diseases.

CUE-401

Stage not disclosed · Active

Target TGF-β/IL-2

Indications

Autoimmune diseases (Stage not disclosed)

Status note Prioritized autoimmune program; no stage or indication specifics stated in filing.

CUE-500 series (excl. CUE-501)

Stage not disclosed · Active

Partnerships Boehringer Ingelheim: CUE-501 licensed under BI Collaboration and License Agreement (Einstein consented Apr 2025)

Indications

Autoimmune diseases (Stage not disclosed)

Status note Prioritized autoimmune program; no stage stated in filing. CUE-501 licensed to Boehringer Ingelheim.

CUE-100 series (CUE-101, CUE-102)

Stage not disclosed · Active Modality: Immuno-STAT platform molecules

Target HPV/WT1

Partnerships ImmunoScape Pte. Ltd.: option exercised Nov 6, 2025 for licenses to research, develop and commercialize CUE-100 series molecules for all oncology indications

Indications

Oncology (Stage not disclosed)

Status note No clinical stage stated in filing.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Ikarian Capital	104,364	+104,364	0.54%	2026-08-14
ADAR1 Capital Management	55,193	+55,193	0.08%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

CUE — Cue Biopharma Inc.

Balance sheet

Price history

Pipeline assets

Institutional holders